Clinical Trial Update: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pembrolizumab in participants with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING